Cwm LLC Purchases 3,671 Shares of Phreesia, Inc. (NYSE:PHR)

Cwm LLC increased its position in shares of Phreesia, Inc. (NYSE:PHR) by 994.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,040 shares of the company’s stock after acquiring an additional 3,671 shares during the quarter. Cwm LLC’s holdings in Phreesia were worth $103,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Invesco Ltd. raised its holdings in Phreesia by 0.9% during the 4th quarter. Invesco Ltd. now owns 40,249 shares of the company’s stock worth $1,013,000 after buying an additional 357 shares during the period. NewEdge Advisors LLC raised its holdings in Phreesia by 12.1% during the 4th quarter. NewEdge Advisors LLC now owns 4,256 shares of the company’s stock worth $107,000 after buying an additional 459 shares during the period. Arcadia Investment Management Corp MI raised its holdings in Phreesia by 0.7% during the 1st quarter. Arcadia Investment Management Corp MI now owns 92,770 shares of the company’s stock worth $2,371,000 after buying an additional 615 shares during the period. QRG Capital Management Inc. raised its holdings in Phreesia by 8.0% during the 1st quarter. QRG Capital Management Inc. now owns 11,118 shares of the company’s stock worth $284,000 after buying an additional 827 shares during the period. Finally, Johnson Financial Group Inc. raised its holdings in Phreesia by 381.3% during the 4th quarter. Johnson Financial Group Inc. now owns 1,131 shares of the company’s stock worth $28,000 after buying an additional 896 shares during the period. Institutional investors own 92.10% of the company’s stock.

Phreesia Price Performance

NYSE:PHR opened at $27.02 on Thursday. Phreesia, Inc. has a 1-year low of $17.07 and a 1-year high of $30.53. The company has a current ratio of 1.95, a quick ratio of 1.95 and a debt-to-equity ratio of 0.02. The firm has a fifty day simple moving average of $26.72 and a 200 day simple moving average of $26.41. The stock has a market capitalization of $1.61 billion, a PE ratio of -36.51 and a beta of 0.72.

Phreesia (NYSE:PHR) last released its quarterly earnings data on Wednesday, May 28th. The company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.06. Phreesia had a negative net margin of 9.83% and a negative return on equity of 16.23%. The firm had revenue of $115.94 million during the quarter, compared to analysts’ expectations of $115.00 million. During the same period in the previous year, the business posted ($0.05) earnings per share. The company’s revenue for the quarter was up 14.5% compared to the same quarter last year. On average, research analysts expect that Phreesia, Inc. will post -1.1 EPS for the current fiscal year.

Insider Activity

In other Phreesia news, Director Michael Weintraub sold 7,431 shares of Phreesia stock in a transaction on Monday, June 9th. The shares were sold at an average price of $27.51, for a total transaction of $204,426.81. Following the completion of the transaction, the director directly owned 143,039 shares of the company’s stock, valued at $3,935,002.89. The trade was a 4.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Lisa Egbuonu-Davis sold 2,802 shares of Phreesia stock in a transaction on Thursday, June 26th. The stock was sold at an average price of $27.67, for a total transaction of $77,531.34. Following the transaction, the director directly owned 22,037 shares of the company’s stock, valued at approximately $609,763.79. This trade represents a 11.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 53,804 shares of company stock valued at $1,510,733. 5.50% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on PHR. Citigroup reiterated a “buy” rating on shares of Phreesia in a report on Wednesday, May 28th. Canaccord Genuity Group lowered their price objective on shares of Phreesia from $35.00 to $34.00 and set a “buy” rating on the stock in a report on Thursday, May 29th. KeyCorp lifted their price objective on shares of Phreesia from $28.00 to $35.00 and gave the company an “overweight” rating in a report on Monday, July 14th. Wall Street Zen upgraded shares of Phreesia from a “hold” rating to a “buy” rating in a report on Sunday, June 1st. Finally, Truist Financial lifted their price objective on shares of Phreesia from $34.00 to $35.00 and gave the company a “buy” rating in a report on Thursday, May 29th. Eleven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Phreesia has an average rating of “Buy” and an average price target of $32.27.

Phreesia Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.